tislelizumab + BGB-A445

tislelizumab + BGB-A445 is a combination therapy under clinical investigation for advanced solid tumors, including nasopharyngeal carcinoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). Tislelizumab is a monoclonal antibody targeting the PD-1 receptor, functioning as an immune checkpoint inhibitor. BGB-A445 is a novel, humanized IgG1 monoclonal antibody that acts as an agonist of the co-stimulatory immune receptor OX40. BGB-A445 binds to a membrane-proximal, non-blocking site on OX40, which does not compete with the endogenous OX40 ligand. This agonist mechanism promotes T-cell proliferation, survival, activation, and depletion of intratumoral regulatory T cells, enhancing antitumor immune responses. The combination aims to synergistically activate T cells (via OX40 agonism) and relieve immune suppression (via PD-1 blockade). Preliminary studies show manageable safety and encouraging antitumor activity, particularly in nasopharyngeal carcinoma[1][2][3][4][5].